Загрузка...
Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1
Thrombosis is a leading cause of death worldwide [1]. Recombinant tissue-type plasminogen activator (tPA) is the FDA-approved thrombolytic drug for ischemic strokes, myocardial infarction and pulmonary embolism. tPA is a multi-domain serine protease of the trypsin-family [2] and catalyses the critic...
Сохранить в:
| Опубликовано в: : | Data Brief |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Elsevier
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4731420/ https://ncbi.nlm.nih.gov/pubmed/26909366 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.dib.2015.12.050 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|